Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 (March 29, 2023) | By Ana Mulero. Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1 (adenosine deaminase acting on RNA). The goal is to turn cold tumors hot.
The Microbiome Mavericks: How These Startups Are Rewriting the Rules of Medicine and Health.
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B (March 28, 2023) | By Rosemary Scott. Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop several targeted radioligand therapies in oncology. The pair will use Bicycle’s proprietary bicyclic peptide (Bicycle) technology to develop what it calls Bicycle radio-conjugates (BRCs)
By Ross Youngs, March 24, 2023. Engineers Versus Scientists ChatGPT Just some leading questions to ChatGPT with responses and pushback. A fun Friday read. I am focused on executing a new technology to bring the best small molecules into drug discovery research, and funding sources always ask what is your clinical proof – or what is
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy (March 21, 2023) | By Tristan Manalac. Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors. The partnership represents BioNTech’s return to its oncology roots. Though BioNTech is
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets of interest (March 20, 2023) | By BUSINESS WIRE. LONDON–(BUSINESS WIRE) — CHARM Therapeutics (“CHARM”), a 3D deep learning biotechnology company discovering and developing transformational
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. (March 15, 2023) | By JIM CORNALL. Seagen is a global biotechnology company that discovers, develops, and commercializes cancer medicines. The boards of
By Ross Youngs, March 5, 2023. Natural Small Molecule Complexity – Evolution Keeps What Works For decades the promise of obtaining the genetic codes of organisms created a narrative that cures and treatments would quickly follow. The human genome project had a lofty promise and failed to meet even the slightest realization of cures and treatments.